Literature DB >> 6284295

Maternal anti-D concentrations and outcome in rhesus haemolytic disease of the newborn.

P Bowell, J S Wainscoat, T E Peto, H H Gunson.   

Abstract

The relation between maternal anti-D concentrations, measured against the British working standard, and outcome of rhesus-sensitised pregnancies was studied. There is a clear relation between increasing anti-D concentrations and the chance of a severely affected baby. Of those pregnancies (78) where serial anti-D concentrations remained below 4 IU/ml, no baby had a cord haemoglobin below 10 g/dl and three had exchange transfusions. In contrast, of those mothers (106) with anti-D concentrations above 4 IU/ml, 23 had babies with a cord haemoglobin below 10 g/dl and 79 babies had exchange transfusions. It is suggested that those pregnancies where anti-D concentrations remain below 4 IU/ml represent a relatively safe group in which amniocentesis may be avoided.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6284295      PMCID: PMC1498991          DOI: 10.1136/bmj.285.6338.327

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  11 in total

1.  Antibody protein levels in the maternal serum in rhesus iso-immunization.

Authors:  I D Fraser; G H Tovey; W J Lockyer; D F Sobey
Journal:  J Obstet Gynaecol Br Commonw       Date:  1972-12

2.  Liquor bilirubin levels and false prediction of severity in rhesus haemolytic disease.

Authors:  B R Pridmore; E G Robertson; W Walker
Journal:  Br Med J       Date:  1972-07-15

3.  Automated detection of blood group antibodies.

Authors:  W L Marsh; M Nichols; W J Jenkins
Journal:  J Med Lab Technol       Date:  1968-10

4.  Use of discriminant analysis in relating maternal anti-D levels to the severity of haemolytic disease of the Newborn.

Authors:  G Morley; M Gibson; D Eltringham
Journal:  Vox Sang       Date:  1977       Impact factor: 2.144

5.  Observations on the reproducibility of the bromelised test cell anti-D assay using the auto-analyser.

Authors:  H H Gunson; P K Phillips; F Stratton
Journal:  Vox Sang       Date:  1974       Impact factor: 2.144

6.  Quantitative measurement of anti-D during pregnancy using a low ionic strength autoanalyser system.

Authors:  R Douglas; J M Staveley
Journal:  N Z Med J       Date:  1972-09

7.  Prediction of the severity of rhesus haemolytic disease by means of antibody titrations performed on the Autoanalyzer.

Authors:  L A Tovey; W K Haggas
Journal:  Br J Haematol       Date:  1971-01       Impact factor: 6.998

8.  Deaths from rhesus haemolytic disease in England and Wales in 1977: accuracy of records and assessment of anti-D prophylaxis.

Authors:  C Clarke; A G Whitfield
Journal:  Br Med J       Date:  1979-06-23

9.  A case for the antenatal administration of anti-D immunoglobulin to primigravidae.

Authors:  L A Tovey; J M Taverner
Journal:  Lancet       Date:  1981-04-18       Impact factor: 79.321

10.  The International Standard for anti-Rh (anti-D) Incomplete Blood-Typing Serum.

Authors:  K L Goldsmith; A E Mourant; D R Bangham
Journal:  Bull World Health Organ       Date:  1967       Impact factor: 9.408

View more
  5 in total

1.  Incidence of rhesus immunisation after genetic amniocentesis.

Authors:  A Tabor; D Jerne; J E Bock
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-30

2.  Rh(D) haemolytic disease of the newborn: the changing scene.

Authors:  S J Urbaniak
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-06

3.  Management of severe rhesus disease by intravascular fetal transfusion: a report of 2 cases.

Authors:  P F Chamberlain; K H Nicolaides; S V Long
Journal:  Ir J Med Sci       Date:  1988-05       Impact factor: 1.568

Review 4.  Haemolytic disease of newborn.

Authors:  A Narang; N Jain
Journal:  Indian J Pediatr       Date:  2001-02       Impact factor: 1.967

5.  The British Standard for (European Conformity[CE] Marked) Anti-D: Its rarely discussed but important role in quantitating anti-D in patient plasma.

Authors:  Bernard Fox; Jason Hockley; Lucy Studholme
Journal:  Transfus Med       Date:  2019-11-26       Impact factor: 2.019

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.